

FinePointe Inhalation Tower and Whole-Body Plethysmography

The Ultimate Solution for Coronavirus Research

The COVID-19 pandemic has impacted all our lives. According to the World Health Organization Coronavirus Dashboard, there have been over 130 million confirmed cases worldwide, including a devastating nearly 3 million deaths. Researchers around the globe have worked tirelessly to develop therapeutics and vaccines to combat this latest infectious disease. DSI's cutting-edge Inhalation Exposure and Respiratory solutions are at the forefront of these crucial advancements.

Virus/Vaccine/Therapeutic Administration and Animal Model Development


DSI's Inhalation Tower allows for targeted, precise, uniform, and repeatable nasal exposure of SARS-CoV-2, as well as real-time monitoring of viral load to target and assess the amount of aerosol the animal has inhaled.

- Live plethysmography and concentration monitoring allows for real-time, instantaneous calculation of viral, or compound load via the Accumulated Inhaled Aerosol (AIA) parameter.
- Prevents rebreathing and eliminates CO2 buildup
- Stackable design allows for higher throughput by exposing many animals at once without sacrificing precision
- Seamless integration with vibrating mesh nebulizers that are gentle on viruses
- Patented Allay restraint allows for more animal comfort, promoting natural breathing and exposure to only the nose

Quantitatively Measure Disease Progression and Vaccine/Therapeutic Effectiveness

Once the animal model has been created, you can develop a quantitative understanding of the illness by measuring various parameters to chart disease progression over time. The FinePointe Whole Body Plethysmography system is the industry leader in unrestrained, high-throughput, longitudinal measurements of respiratory parameters.

- Single controller with fully integrated data collection, bias flow pumps, and aerosol challenges
- Low-noise Halcyon pneumotach design ensures the best signal for reliable data processing.
- Automated calibration with a single button click ensures accurate and consistent data, every time.
- Derived parameters to evaluate viral respiratory pathogenesis in SARS-CoV infections
 - **PenH** (enhanced pause)
 - **EF50** (mid-tidal expiratory flow)
 - **Rpef** (ratio of time to peak expiratory flow relative to expiratory time)
- FinePointe software's automated reporting allows for easy visibility to changes in breathing over the incubation period and after.



The most reputable researcher facilities around the world have trusted DSI's Buxco FinePointe Inhalation and Whole-Body Plethysmography to study infectious diseases:



Data Sciences International
 119 14th St NW Suite 100 St.
 Paul, MN 55112 USA
 Telephone: 651-481-7400
 Fax: 651-481-7404

Sales:
 Sales@datasci.com eu-
 rope-sales@datasci.com
 dsi-shanghai-office@datasci.com
Technical Support:
 support@datasci.com
Web: www.datasci.com

© 2021 Data Sciences International
 a division of Harvard Bioscience, Inc.
 Product information is subject to
 change without notice.